Systemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE

Nat Rev Rheumatol. 2016 Nov 22;12(12):700-702. doi: 10.1038/nrrheum.2016.191.


Despite conflicting evidence from clinical trials, rituximab continues to be used off-label in the treatment of systemic lupus erythematosus (SLE). A new study has now investigated the use of this drug for SLE in Europe, including indications for use and patient characteristics.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment